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Abstract
Background: Venous thromboembolism (VTE) is a multicausal disease which recurs. Hematocrit is associated with a
thrombotic risk. We aimed to investigate if hematocrit is associated with the recurrence risk.
Methods: Patients with a first VTE were followed after anticoagulation. Patients with VTE provoked by a transient risk factor,
natural inhibitor deficiency, lupus anticoagulant, homozygous or double heterozygous defects, cancer, or long-term
antithrombotic treatment were excluded. The study endpoint was recurrent VTE.
Results: 150 (23%) of 653 patients had recurrence. Only high hematocrit was significantly associated with recurrence risk
[hazard ratio (HR) for 1% hematocrit increase with the third tertile 1.08; 95% CI 1.01–1.15]. No or only a weak association for
hematocrits within the first and second tertile was seen (HR 1.03; 95% CI 0.97–1.09, and 1.07; 95% CI 1.00–1.13). Hematocrit
was associated with recurrence risk only among women. After five years, the probability of recurrence was 9.9% (95% CI
3.7%–15.7%), 15.6% (95% CI 9.7%–21.2%) and 25.5% (95% CI 15.1%–34.6%) in women, and was 29.2% (95% CI 21.1%–
36.5%), 30.1% (95% CI 24.1%–35.7%) and 30.8% (95% CI 22.0%–38.7%) in men for hematocrits in the first, second and third
tertile, respectively. Men had a higher recurrence risk (1.9; 95% CI 1.1–2.7; p=0.03), which dropped by 23.5% after
adjustment for hematocrit. Hematocrit was not a significant mediator of the sex-difference in recurrence risk (p=0.223).
Conclusions: High hematocrit is associated with the recurrence only in women. The different recurrence risk between men
and women is possibly partly explained by hematocrit.
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Introduction
Venous thromboembolism (VTE) is a multicausal disease,
which tends to recur. The risk of recurrence depends on the
severity and number of risk factors that are present in a patient at a
certain time point. Meanwhile, the impact of many acquired and
genetic risk factors on the recurrence risk has been defined [1], and
prediction models that integrate these factors have been developed
[2,3]. With regard to clinical relevance, the patient’s sex is one of
the most important factors, as men have a higher recurrence risk
than women [4]. Overall, the sex-related risk increase is about 2-
fold [5], is present in all age groups, is not related to hormone
contraceptive intake at the first thrombotic event, and independent
also of other established risk factors [6].
Men and women differ with regard to hematocrit levels. The
difference is most pronounced between premenopausal women
and age-matched men [7]. Hematocrit correlates with the
thrombotic risk. High hematocrit is associated with increased
plasma viscosity and platelet reactivity [8,9]. Patients with
myeloproliferative disorders, particularly those with polycythemia
vera, are at high risk of thrombosis [10,11]. In a case control study
the percentage of study participants with a hematocrit above 45%
was higher in DVT patients (43%) than in healthy controls (27%)
[12]. High hematocrit was a risk factor of a first VTE in the
general population [13].
We hypothesized that hematocrit may be causally related to the
recurrence risk, which may then provide an explanation for the
risk difference between men and women. The aim of our study
was to investigate the association between hematocrit and the risk
of recurrent VTE and to evaluate the effect of hematocrit on the
recurrence risk in men and women.
Methods
Patients and study design
This study was performed within the frame of the Austrian
Study on Recurrent Venous Thromboembolism (AUREC), a large
prospective ongoing multi-centre cohort study initiated in 1992.
Recruitment of new patients was stopped in September 2008. The
present analysis considers follow-up data collected until October
2009. Patients were included, when they were older than 18 years
of age, had a symptomatic objectively confirmed VTE, and were
treated with anticoagulants for 3 to 18 months. Exclusion criteria
were a previous episode of VTE; VTE related to surgery, trauma,
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deficiency of antithrombin, protein C, or protein S, presence of the
lupus anticoagulant or homozygosity or double heterozygosity for
factor V Leiden and/or factor II G20210A; cancer at time of
enrolment; or requirement for long-term antithrombotic treatment
for other reasons than VTE. Patients entered the study at the time
of discontinuation of anticoagulation. At study entry, a detailed
medical history was obtained, and a physical examination and
body mass index (BMI) calculation were performed. According to
their smoking habits at time of index-VTE patients were
categorized as smokers or non-smokers. Three weeks after
withdrawal of anticoagulation, they were screened for deficiency
of antithrombin, protein C, or protein S, the lupus anticoagulant,
factor V Leiden and factor II G20210A and a complete blood
count was performed. Patients were seen at six-month intervals for
the first year and once a year thereafter. They were given detailed
written information on symptoms of VTE and were asked to
report immediately if such symptoms occurred. Female patients
were strongly discouraged from intake of estrogen-containing oral
contraceptives or hormone replacement therapy. Patients received
thromboprophylaxis with a low-molecular-weight heparin during
high-risk situations such as surgery, trauma, prolonged immobi-
lization or long-haul air travel. The ethics committee of the
Medical University of Vienna approved the study and all patients
gave written informed consent prior to inclusion in the study.
Diagnosis of first venous thromboembolism
As previously described in more detail [5], the diagnosis of VTE
was established by a positive finding on venography or color
duplex sonography.
The diagnosis of PE was established by ventilation-perfusion
lung scanning or by spiral computed tomography (CT) scan.
Study end points
The end point of the study was recurrent symptomatic DVT
confirmed by venography or color duplex sonography, or
recurrent symptomatic PE confirmed by multi-slice computed
tomography, ventilation-perfusion lung scanning or autopsy.
Laboratory analysis
Venous blood from fasting patients was collected into EDTA
tubes or in 1:10 volume of 0.11 mM trisodium citrate and
immediately centrifuged for 20 min at 20006g. Aliquots of plasma
were stored at 280uC until analysis.
Complete blood count including hematocrit was determined in
EDTA blood using a Sysmex XE-2100-analyser.
Screening for factor V Leiden and prothrombin G20210A and
measurement of antithrombin, protein C and protein S were
carried out by standard methods. The diagnosis of the lupus
anticoagulant was based on criteria of the International Society on
Thrombosis and Haemostasis [14].
Statistical analysis
Categorical data were compared among groups using contin-
gency-table analyses (the chi-square test). Continuous data
(presented as means 6 SD) were compared by means of Mann-
Whitney U tests. Survival-time methods were used to analyse the
time to recurrence among patients with a subsequent episode of
VTE (uncensored observation) or the duration of follow-up among
patients without recurrence (censored observations) [15]. Data on
patients who left the study or who were lost to follow-up were
censored at the time of withdrawal. The probability of recurrence
was estimated according to the method of Kaplan and Meier [16].
To test for homogeneity between strata, we applied the log-rank
test. Univariate and multivariate Cox proportional-hazards model
were used to analyse the association between hematocrit and the
risk of recurrent VTE.
To assess the effect of hematocrit and sex on the recurrence risk
and to investigate linearity or non-linearity in case of an
association, we accounted for a possibly non-linear effect of
hematocrit by non-linear estimation via fractional polynomials.
The fractional polynomial (FP) technique is extensively described
elsewhere [17], here we just briefly describe its outline. Instead of
using hematocrit as linear in the Cox regression, this technique
evaluates several pre-specified transformations of hematocrit, and
selects that transformation or combination of transformations that
leads to the best-fitting model. After determining the best
transformation of hematocrit, product terms of sex and the
transformed hematocrit levels were included in the model to
evaluate and test the interaction of sex and hematocrit. The final
nonlinear interaction model was used to estimate the cumulative
recurrence rates of women having hematocrits of 36%, 40% and
43%, corresponding to the tertile means of women, and of men
having hematocrits of 41%, 44% and 47%, corresponding to the
tertile means in men. In these computations, average covariate
values were inserted for all other variables (age, BMI, location of
initial VTE, smoking status, factor V Leiden).
Mediation of the sex effect by hematocrit was evaluated by
comparing the hematocrit-adjusted and -unadjusted log hazard
ratios of sex in the Cox regression model. A P-value for the null
hypothesis that the hematocrit-adjusted and –unadjusted log
hazard ratios of sex are equal (no mediation) was obtained using
the method of Lin et al [18]. All P values were two-tailed, and
were considered as indicating statistical significance if lower than
0.05. The statistical software R 2.9.2 (R development core team,
Vienna, 2009, www.r-project.org) and the R package coxphf
(written by G. H.), which combines the fractional polynomial
technique with a small-sample bias-correction method in Cox
regression, was used for statistical analysis [19]. In addition, SPSS
software, version 15.0, was used.
Results
Study population
A total of 653 patients, 427 (65%) men and 226 (35%) women,
with a first unprovoked DVT and/or PE were followed for a mean
of 43 months(Table 1).171 patients left the study because of newly
diagnosed cancer (17), pregnancy (5), antithrombotic therapy for
reasons other than VTE (94) or loss to follow-up (43). 12 patients
died for reasons other than VTE. Patients were followed until the
time of exclusion or death, when data were censored.
Recurrence of venous thromboembolism
Symptomatic VTE recurred in 150 (23%) patients. Isolated
DVT occurred in 77 and PE with or without DVT in 73 patients,
3 of them were fatal. Male sex conferred a hazard ratio (HR) of
recurrence of 1.9 (95% CI 1.3–2.9; p=0.001). The univariate HR
for age (per decade), BMI, smoking status, factor V Leiden and
factor II G20210A were 0.97 (95% CI 0.86–1.09, p=0.63), 1.04
(95% CI 1.0–1.07, p=0.03), 0.98 (95% CI 0.69–1.41, p=0.93),
1.67 (95% CI 1.19–2.35, p=0.003), and 1.05 (95% CI 0.52–2.14,
p=0.89), respectively.
Hematocrit and risk of recurrent VTE
In a Cox proportional hazards model, the HR of recurrence was
1.07 (95% CI 1.02–1.13; p=0.004) for each 1% increase in
hematocrit. In a nonlinear modeling using the technique of
Hematocrit and Risk of Recurrent Venous Thrombosis
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hematocrit was not constant over the range of hematocrit values,
but depended on whether hematocrit was low or high. While in a
multivariable model (adjusted for sex, age, BMI, location of first
VTE, smoking status and factor V Leiden) no association between
a 1% increase of hematocrit within the lowest tertile (mean value
38.5%) was seen, the association was stronger for hematocrits in
the second tertile (mean value 42.5%) and was significant in the
highest tertile (mean value 46.0%): HR 1.03 (95% CI 0.97–1.09),
1.07 (95% CI 1.00–1.13) and 1.08 (95% CI 1.01–1.15),
respectively.
Recurrence risk in women and men according to
hematocrit. Hematocrit was significantly higher in men than
in women (43.7% vs. 39.7%, p,0.001), and the frequency
distribution of hematocrit differed substantially (Figure 1). We
therefore hypothesized that the effect of sex on recurrence risk
might be explained by the sex-specific hematocrit levels and the
relationship between hematocrit and risk of recurrence.
VTE recurred in 32 of the 226 women (14.2%) and in 118 of
the 427 men (27.6%). Male sex remained a significant predictor of
the recurrence risk after adjustment for hematocrit [HR 1.7 (95%
CI 1.1–2.7), p=0.03] using linear or non-linear values. Although
the HR of recurrence for male sex dropped from 1.9 to 1.7 after
adjustment for hematocrit, the formal test for mediation did not
reach significance (p=0.223).
We further investigated whether the effect of hematocrit on
recurrence risk differed between women and men using interac-
tion analysis. Here, product terms of the transformed hematocrit
values with sex (H16sex and H26sex) were introduced to the
model. If different from zero, these product terms indicate a sex-
related difference in the association between hematocrit and the
risk of recurrence. Indeed, the two terms were simultaneously
significantly different from zero (p=0.024). This implied that the
risk of recurrence associated with a 1% increase in hematocrit not
only depended on the level of hematocrit but also on the sex of the
patients. In order to illustrate this nonlinear sex-dependent effect
of hematocrit, we computed the HRs at the sex-specific hematocrit
tertile mean values (36.3%, 40.0% and 42.9% in women; 40.7%,
43.6% and 46.8% in men) (Table 2). While hematocrit had no
relevant impact on the recurrence risk in men, its effect was strong
and nonlinear in women. From this final Cox regression model we
also derived the five-year cumulative recurrence rates in women
and in men (Figure 1). Furthermore, we estimated and depicted
the cumulative recurrence risk for women with hematocrits of
36%, 40% and 43% (corresponding to the tertile means of female
patients), and for men of 41%, 44% and 47% (corresponding to
the tertile means of men) (Figure 2). After five years, the
probability of recurrence was 9.9% (95% CI 3.7%–15.7%),
15.6% (95% CI 9.7%–21.2%), and 25.5% (95% CI 15.1%–
34.6%) in women with hematocrit ranging in the lowest to the
highest tertile and was 29.2% (95% CI 21.1%–36.5%), 30.1%
(95% CI 24.1%–35.7%), and 30.8% (95% CI 22.0%–38.7%) in
men within the respective tertiles.
Discussion
Our study shows that hematocrit is associated with the risk of
recurrence in patients with a first unprovoked VTE. Herewith, we
provide further clinical evidence that corroborates the relation
between hematocrit and the risk of VTE [11,12]. We considered
several factors that might affect hematocrit and could therefore
confound our results. We excluded patients with cancer and
pregnancy related thrombosis as well as those who required
anticoagulant treatment because of an underlying heart condition.
Hematocrit was determined after discontinuation of anticoagula-
tion, i.e. at least three months after VTE, which precludes an effect
of the acute thrombotic event on hematocrit. We adjusted our
analyses for age, BMI, smoking status, and factor V Leiden, but
the association between hematocrit and recurrence risk was
independent of these potential confounders. Nevertheless, whether
or not this relation is causal remains open.
Notably, the association between hematocrit and recurrence risk
was dependent on the level of hematocrit and the sex of the
patient. First, the relation between hematocrit and recurrence risk
was not constant. While low hematocrits (values within the first
tertile) were not associated with the recurrence risk, hematocrits
within the highest tertile were strongly predictive. Second,
hematocrit was useful to stratify patients according to recurrence
risk only in women. Women with hematocrit less than 36%
(corresponding to the upper limit of the first tertile) had a very low
probability of recurrence corresponding to 9.9% (95% CI 3.7%–
15.7%) after five years. In men, no association between hematocrit
and recurrence risk was found. These findings are in contrast to
Table 1. Patient characteristics.
Total cohort Women Men p for sex difference
(n=653) (n=226) (n=427)
Age (yrs) 52 6 14 55 6 15 51 6 14 0.03
Location of first VTE DVT distal – n(%) 110 (17) 46 (20) 64 (15)
DVT proximal – n(%) 254 (39) 70 (31) 184 (43) 0.01
PE 6 DVT – n(%) 289 (44) 110 (49) 179 (42)
Duration of anticoagulation (mo) 7.5 6 2.4 7.6 6 2.6 7.5 6 2.3 0.6
Observation time (mo) 43 6 33 42 6 35 43 6 32 0.5
Factor V Leiden – n(%) 154 (24) 40 (18) 114 (27) 0.01
Factor II G20210A – n(%) 30 (5) 12 (5) 18 (4) 0.6
Body mass index (kg/m
2)2 7 . 8 6 5.0 28.2 6 6.1 27.6 6 4.3 0.5
Smoking status – n(%) 186 (30) 60 (28) 126 (31) 0.4
Hematocrit (%) 42.3 6 3.6 39.7 6 3.3 43.7 6 2.9 ,0.001
Plus-minus values are means 6 standard deviation.
doi:10.1371/journal.pone.0038705.t001
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and risk of thrombosis was more pronounced in men than in
women [12]. In that study the relationship between hematocrit
and a first rather than recurrent VTE was investigated. While we
included only patients with unprovoked events, in the study by
Braekkan more than 60% had provoked VTE, the proportion of
women who had provoked events was higher than that of men and
data of women who had their VTE during female hormone intake
or pregnancy were also included.
In our study, the risk of recurrence was 1.9-fold higher in men
than in women. This is lower than what we previously published
[4], but is due to exclusion of women who had VTE during female
hormone intake in the present analysis.
Hematocrit in average was higher in men than in women
(43.7% vs. 39.7%). Nevertheless, our hypothesis that the sex-
difference in recurrence rates could be explained by hematocrit
was only partly supported by our analyses. When we adjusted the
regression analysis of the recurrence risk between men and women
for hematocrit, the risk was still significantly higher among men
Figure 1. Five-year cumulative recurrence risk as estimated from the Cox regression model in women (left) and men (right) at
various hematocrits, adjusted for location of first venous thromboembolism, body mass index, age, factor V Leiden, and smoking
status. The gray-shaded area corresponds to the 95% confidence intervals. The histograms at the bottom show the frequency distribution
(n=number of patients) of hematocrit in women and men.
doi:10.1371/journal.pone.0038705.g001
Figure 2. Cumulative recurrence rates (as estimated from the Cox regression model) in women and men according to tertile mean
values of hematocrit, adjusted for location of first venous thromboembolism, body mass index, age, factor V Leiden, and smoking
status.
doi:10.1371/journal.pone.0038705.g002
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risk difference was not significant, which indicates that hematocrit,
if at all, is only a minor mediator of the sex effect on recurrence
risk. Some strengths and limitations of the current study have to be
addressed. Our results are based on a large study population with
a long observation time. An objective diagnosis and end point
verification was established in all patients. Hematocrit was
measured only once shortly after discontinuation of anticoagula-
tion. We therefore could not account for variations in hematocrit
over time and a potential association on the risk of recurrent VTE.
Potential confounders of the hematocrit including pack years of
smoking, lung disease, kidney function, diuretic use or chronic
inflammatory disease were not collected systematically. We did not
evaluate the association between other variables of red blood cell
characteristics. Our findings cannot be extrapolated to patients
with a provoked VTE or those with a strong thrombophilic defect,
as these patients were excluded. The Austrian Study on recurrent
Venous Thromboembolism is a hypothesis-generating cohort
study, which precludes predefinition of certain cutoff values.
In summary, we found a nonlinear and sex-dependent
relationship between hematocrit and risk of recurrent VTE
among patients with a first unprovoked venous thrombosis.
Women with low hematocrit are at low risk of recurrence.
Hematocrit is not predictive for recurrence in men. The difference
in the risk of recurrent VTE between men and women is possibly
partly explained by the sex-related difference in hematocrit.
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Table 2. Risk of recurrent venous thromboembolism accounting for the nonlinear interaction of hematocrit* and sex{.
Male patients Female patients
Tertile Mean hematocrit (%) Hazard ratio{ Mean hematocrit (%) Hazard ratio{
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1 40.7 1.01 (0.93, 1.10) 36.3 1.11 (0.99, 1.23)
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